GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
Paramount Skydance Appoints Rene Augustine as SVP of Global Public Policy Amid Warner Bros Takeover Battle 
Grok AI Market Share Surges as xAI Faces Scrutiny Over Image Generation Controversy 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
Sachem Head Boosts Warner Bros. Discovery Stake Amid Netflix Deal and Paramount Bid 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
Lockheed Martin Secures $101M in U.S. Defense Contracts for AEGIS, F-35, and Missile Systems 
Valero Energy Expands Venezuelan Crude Imports as U.S. Sanctions Ease 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Anduril Eyes $60 Billion Valuation in New Funding Round to Expand Defense Manufacturing and Autonomous Fighter Jet Development 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
NEW YORK, April 20, 2018 -- Caelum Biosciences, Inc. (“Caelum”), a Fortress Biotech, Inc. Company developing treatments for rare and life-threatening diseases, today announced it has confidentially submitted a draft registration statement on Form S-1 to the Securities and Exchange Commission (the “SEC”) related to its proposed initial public offering. The number of shares of stock and the price range for the proposed offering have not yet been determined. The proposed offering is subject to, among other things, completion of SEC review process and market conditions.
This press release is being made pursuant to and in accordance with Rule 135 under the Securities Act of 1933, as amended, and does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.
Contacts:
Caelum Biosciences, Inc.
Michael Spector, President & Chief Executive Officer
(212) 574-2811
[email protected]
Laura Bagby, Media Relations
6 Degrees
(312) 448-8098
[email protected]
